Monday, 8 September 2008

Phase II Results Of COL-144 Presented At European Headache And Migraine Trust International Congress 2008

�CoLucid Pharmaceuticals, Inc., an innovative biotechnology company
focusing on therapies for cardinal nervous system disorders, announced Phase
II results of its tether compound COL-144 in the treatment of acute hemicrania.
Results demonstrated that COL-144 was safe and good in relieving
migraine headaches. COL-144 is a first-in-class Neurally Acting Anti- Migraine
Agent (NAAMA), which unlike triptans, exhibits anti-migraine activity without
causation vasoconstriction. COL-144 is a highly potent and selective 5HT1F
receptor agonist. The studies were presented in poster presentations at the
European Headache and Migraine Trust International Congress 2008 in London,
Sept. xlvii, 2008.





"In the Phase II study, the legal age of patients experienced sick headache
relief 20 to 40 minutes afterwards dosing and COL-144 was generally
well-tolerated," Alison Pilgrim, BM, BCh, DPhil, chief medical military officer at
CoLucid, said. "The study indicates that COL-144 may be a treatment option
for all patients including those who don't respond to or are contraindicated
for the electric current standard of care."





The randomized, double blind study evaluated 130 sick headache patients.
Patients were non on prophylaxis and received 2.5 to 45 mg of COL-144 or
placebo as an intravenous infusion all over 20 minutes as first-line treatment of
an intense migraine tone-beginning. The principal end-point parameter was headache
response, defined as a reduction in headache rigor from tame to austere
at baseline to modest or no headache at two hours after foundation of infusion
of survey drug.





A higher proportion of patients showed a headache response at two hours
post dose in the 10 mg, 20 mg, 30 mg and 45 mg groups compared to placebo
(54.2 to 75% vs. 45.2%) with a statistically significant running association
betwixt response rates and dose levels (p= 0.0126). The adaptative study blueprint
used could identify doses giving a headache reply in 50-75% of patients.
It did not explore the maximum possible efficacy of the drug.





COL-144 was generally well-tolerated with no unplayful adverse events or
withdrawals due to non-serious adverse events. The most vulgar adverse event
was paresthesia, which was usually mild and transient, resolving quickly
after cessation of the infusion. No patient reported triptan-like chest
symptoms in relation to the COL-144 infusion. No clinically significant
changes were seen in vital signs or ECG parameters.





"We identified doses of 20 mg and higher as doses of interest for further
evaluation in future studies, and we plan to persist in the clinical
development of COL-144, victimisation an unwritten formulation," added Dr. Pilgrim.


About CoLucid Pharmaceuticals, Inc.




CoLucid Pharmaceuticals was founded in December 2005 by Pappas Ventures
to bring forward innovative do drugs candidates with the potential to provide safe and
effective discourse for central nervous system (CNS) disorders. The company's
pipeline includes COL-144, a novel intervention for megrim headache, and a
conjugate stigmine platform that has generated a series of preclinical
candidates for the treatment of sleep/wake disorders, chronic nuisance,
Alzheimer's disease and psychiatrical disorders.

CoLucid Pharmaceuticals


More information

Friday, 29 August 2008

Arlo Guthrie to Perform 'Boy's Night Out' Saturday, August 30th at the Orange County Great Park

IRVINE, Calif., Aug. 25 -- Legendary American tribe singer
Arlo Guthrie is place to perform at the Orange County Great Park on Saturday
August 30th at 8:00 p.m. as part of the Great Park Night Flight Concert
Series. Attendance and parking are release to the public.

Arlo is best known for his epic musical soliloquy Alice's Restaurant.
Three generations of Guthrie's will perform at the Great Park, Arlo, his
son Abe, and grandson Krishna. They will highlight the performance with a
drink to Arlo's father, Woody Guthrie, by singing the long time favorite
"This Land Is Your Land".

In 2006 Arlo, Abe and Krishna staged the "Boy's Night Out" tour across
Europe, and at present this go comes to America for nine shows only. The Orange
County Great Park is the only when California performance.

Over the past 20 years, Arlo's son Abe has performed keyboard
concomitant and powerful supporting vocals along with his dad. It was
rare to see an Arlo show without Abe at his side. Arlo, who has just
completed a yearlong Solo Reunion Tour, aforementioned, "Abe is just a great
player. I can't wait to get back to playing together." Krishna Guthrie,
at only seventeen, is already an accomplished musician playing drums and
guitar. He got his beginning drum congeal at deuce; by trio he had already made his
first-class honours degree appearance with his father and grandad on level. Since and so, he
has occasionally joined the menage on point playing drums.

Arlo Guthrie was innate with a guitar in one hand and a harmonica in the
other in Coney Island, Brooklyn, New York in 1947. He is the firstborn son of
America's most beloved singer/writer/philosopher, Woody Guthrie, and
Marjorie Mazia Guthrie. His mother was a professional social dancer with the
Martha Graham Company and founder of The Committee to Combat Huntington's
Disease.

Arlo gave his first base public public presentation at historic period 13 and quickly became
involved in the music that was shaping the world during the 1960s. Arlo
practically lived in the most famous venues of the "Folk Boom" eRA. In New
York City he hung extinct at Gerdes Folk City, The Gaslight and The Bitter End.
In Boston it was Club 47 and in Philadelphia he made places like The 2nd
Fret and The Main Point his household.

Arlo Guthrie's career exploded in 1967 with the release of his album,
Alice's Restaurant, whose title song premiered at the Newport Folk Festival
and helped foster a new commitment to social consciousness and activism
among the '60s generation. Arlo went on to star in the 1969 Hollywood cinema
version of Alice's Restaurant, directed by Arthur Penn.

Though Arlo's definitive interpretation of Steve Goodman's "City of New
Orleans" may get been his only "hit" song in the traditional sense, he has
ne'er the less achieved international stature. The 18 minute "Alice's
Restaurant," spell too long for radio airplay, has become an American
classic.

Over the last-place four decades Arlo has toured end-to-end North America,
Europe, Africa, Asia and Australia winning a broad and dedicated following.
In addition to being an accomplished musician -- playing the piano, six and
twelve-string guitar, harmonica and a xII other instruments -- Arlo is a
natural-born teller whose screaming tales and anecdotes ar woven
seamlessly into his performances.

The Orange County Great Park, which is almost twice the size of it of New
York City's Central Park, testament be a major metropolitan park and the focal
point of the overhaul of the 4,700-acre former Marine Corps Air
Station at El Toro. The Great Park will let in extensive natural areas and
open space in add-on to recreational and cultural uses.

For more information, please go to http://www.ocgp.org.




More info

Tuesday, 19 August 2008

Medarex Announces Initiation Of Phase 2 Clinical Development Program For The Treatment Of Lupus

�Medarex, Inc.
(Nasdaq: MEDX) announced that its collaborator MedImmune, Inc. has
initiated a Phase 2A multi-dose clinical test of MEDI-545 for the
potential handling of systemic lupus erythematosus (SLE or lupus).
MEDI-545 is a fully human antibody generated by Medarex's UltiMAb Human
Antibody Development System(R). Under the footing of the agreement, Medarex
will welcome a milestone payment of an undisclosed amount.



The Phase 2A clinical visitation is intentional to appraise the guard and
tolerability of multiple subcutaneous loony toons schedules of MEDI-545 or placebo
in adult patients with control to austere active lupus. The study will also
assess the effects of MEDI-545 on disease activity in lupus patients. This
randomized, double blind, placebo-controlled run is expected to enrol 80
patients and testament be conducted at 20 sites in the United States.



MedImmune is as well conducting a Phase 1 clinical trial for MEDI-545 in
idiopathic inflammatory myositis, an immunologic disease that involves
chronic muscle fervour, pain and weakness.



"Data from an earlier reported placebo-controlled Phase 1 study
suggested curative activity with single doses in patients with lupus and
demonstrated an acceptable safety profile," said Geoffrey M. Nichol,
M.B.Ch.B., Senior Vice President of Product Development at Medarex. "We are
selfsame excited about the office of the interferon alpha inflammatory tract
and front forward to exploring its potential in treating patients with lupus
and other autoimmune diseases."

About MEDI-545



MEDI-545 (previously known as MDX-1103) is a fully human monoclonal
antibody targeting interferon-alpha. Published data indicate that levels of
interferon-alpha ar elevated in many patients with active SLE and other
autoimmune disorders, and may be associated with disease activity.
Preclinical information from creature models suggest that MEDI-545 may suppress the
abnormal immune activity associated with lupus by binding to multiple
interferon-alpha subtypes seen in the serum of lupus patients.



In November 2004, MedImmune entered into a collaborationism with Medarex
to focal point on two specific antibodies, one of which was MDX-1103 (now known
as MEDI-545). Under the footing of the agreement, MedImmune is responsible
for all ongoing clinical development activities. Prior to the root of
polar studies, Medarex may elect to co-develop the products in refund for
the opportunity to co-promote and to welcome a portion of the commercial
winnings in the United States. In all other cases, Medarex will be entitled
to have milestone payments and royalties.

About Lupus



Approximately 350,000 individuals in the United States are affected
with lupus, a chronic rabble-rousing disease that causes the body to attack
its own tissues and organs, including the skin, joints, blood and kidneys.
Treatments for lupus include anti-inflammatory drug drugs, antimalarials,
corticosteroids and drugs approved for other purposes, such as
immunosuppressive drug agents minded to cancer patients undergoing chemotherapy
or medicines developed to regale arthritis patients. Lupus occurs about 10
times more frequently in adult females than grownup males, and is two to
iII times more common among African Americans, Hispanics, Asians and
Native Americans.

About Medarex



Medarex is a biopharmaceutical company focused on the discovery,
development and potential commercialization of fully human antibody-based
therapeutics to treat life-threatening and debilitating diseases, including
malignant neoplastic disease, inflammation, autoimmune disorders and infectious diseases. Medarex
applies its UltiMAb(R) technology and product evolution and clinical
manufacturing go through to sire, support and potentially commercialise
a broad range of fully human antibody product candidates for itself and its
partners. More than 40 of these therapeutic product candidates derived from
Medarex applied science are in human clinical testing or have had INDs submitted
for such trials, with seven of the almost advanced mathematical product candidates
currently in Phase 3 clinical trials or the subject of regulative
applications for marketing sanction. Medarex is committed to building
value by development a various pipeline of antibody products to address the
world's unmet healthcare needs. For more information about Medarex, visit
its website at http://www.medarex.com.

Statement on Cautionary Factors



Except for the

Saturday, 9 August 2008

Rob Essers

Rob Essers   
Artist: Rob Essers

   Genre(s): 
New Age
   Electronic: Progressive
   



Discography:


Raincolors   
 Raincolors

   Year: 2002   
Tracks: 14


A Lizards Walk   
 A Lizards Walk

   Year: 1997   
Tracks: 3




 





FDA Clears The Pathwork(R) Tissue Of Origin Test For Hard To Identify Tumors

Tuesday, 1 July 2008

Tesco Rejects Fearnley-whittingstalls Chicken Campaign


Tesco has today defeated a proposal by TV cook Hugh Fearnley-Whittingstall to improve the welfare standards for chickens.

Mr Fearnley-Whittingstall attended Tesco's annual general meeting on Friday where he asked shareholders for help in improving the current standards for chickens reared for eating.

In the end though, only ten per cent backed the chef, with the majority supporting the supermarket's current stance.

Campaigners claim that the current conditions at some rearing farms are appalling and need to be urgently improved.

Tesco, the UK's biggest supermarket chain, was criticised earlier this year when it cut the price for a standard whole chicken to just £1.99.

The supermarket counters the criticism by saying its chickens are raised on farms with high standards.

During his TV shows, Mr Fearnley-Whittingstall has continually drawn attention to the conditions in which chickens are kept in intensive battery farms.

At the vote on Friday, the chef hoped to convince shareholders to support the motion which would make Tesco adopt better minimum standards for chickens.


27/06/2008 12:26:51





See Also

Tuesday, 24 June 2008

Djeli Moussa Diawara and Bob Brozman

Djeli Moussa Diawara and Bob Brozman   
Artist: Djeli Moussa Diawara and Bob Brozman

   Genre(s): 
Folk
   



Discography:


Ocean Blues   
 Ocean Blues

   Year: 2000   
Tracks: 11




 





Ved Buens Ende

Friday, 13 June 2008

Bob Brozman and Woody Mann

Bob Brozman and Woody Mann   
Artist: Bob Brozman and Woody Mann

   Genre(s): 
Blues
   



Discography:


Get Together   
 Get Together

   Year: 2000   
Tracks: 15




 





Sex And The City - Cattrall Delighted To Beat Indiana Jones